Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial
International Journal of Clinical Oncology, 04/18/2012Uemura H et al.
Simultaneous administration of zoledronic acid (ZOL) and maximal androgen blockade (MAB) as initial treatment delayed time to progression (TTP) in bone–metastatic prostate cancer patients. Initial treatment with ZOL has the possibility of anti–tumor activity to delay disease progression.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.